Functionally, JQ1 markedly improved tumor recognition by autologous MART-1- and neoantigen-specific CD8<sup>+</sup> TIL, while dampening CD4<sup>+</sup> TIL activation through the downregulation of Cathepsin S (CTSS). Here, CD8A is linked to neoplasm.